ABC | Volume 115, Nº1, July 2020

Short Editorial Rafacho Quercetin Ameliorates Lipid Profile in Rats Arq Bras Cardiol. 2020; 115(1):109-110 1. Joseph SV, Edirisinghe I, Burton-Freeman BM. Fruit polyphenols: A review of anti-inflammatory effects in humans. Crit Rev Food Sci Nutr. 2015;56(3):419-44. 2. Panche AN, Diwan AD, Chandra SR. Flavonoids: an overview. J Nutr Sci. 2016;5:e47. 3. Andres S, Pevny S, Ziegenhagen R, Bakhiya N, Schafer B, Hirsch-Ernst KI, et al. Safety Aspects of the Use of Quercetin as a Dietary Supplement. Mol Nutr Food Res. 2018;62(1). doi.og/10.1002/mnfr.201700447 4. Sahebkar A. Effects of quercetin supplementation on lipid profile: A systematic review and meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr. 2017;57(4):666-76. 5. Lee KH, Park E, Lee HJ, Kim MO, Cha YJ, Kim JM, et al. Effects of daily quercetin-rich supplementation on cardiometabolic risks in male smokers. Nutr Res Pract. 2011;5(1):28-33. 6. Eid HM, Haddad PS. The Antidiabetic Potential of Quercetin: Underlying Mechanisms. Current medicinal chemistry. 2017;24(4):355-64. 7. Yang DK, Kang HS. Anti-Diabetic Effect of Cotreatment with Quercetin and Resveratrol in Streptozotocin-Induced Diabetic Rats. Biomol Ther (Seoul). 2018;26(2):130-8. 8. Gnoni GV, Paglialonga G, Siculella L. Quercetin inhibits fatty acid and triacylglycerol synthesis in rat-liver cells. Eur J Clin Invest. 2009;39(9):761-8. 9. AmiotMJ,RivaC,VinetA.Effectsofdietarypolyphenolsonmetabolicsyndrome features in humans: a systematic review. Obes Rev. 2016;17(7):573-86. 10. Kuipers EN, Dam ADV, Held NM, Mol IM, Houtkooper RH, Rensen PCN, et al. Quercetin Lowers Plasma Triglycerides Accompanied by White Adipose Tissue Browning in Diet-Induced Obese Mice. Int J Mol Sci. 2018;19(6).:1786. 11. Derakhshanian H, Djalali M, Djazayery A, Javanbakht MH, Zarei M, Hekmatdoost A, et al. QuercetinaMelhora o Perfil Lipídico e Apolipoproteico emRatosTratadoscomGlicocorticóidesemAltasDoses.ArqBrasCardiol.2020; 115(1):102-108. 12. FardetL,FeveB.Systemicglucocorticoidtherapy:areviewof itsmetabolicand cardiovascular adverse events. Drugs. 2014;74(15):1731-45. 13. Faludi AA, Izar MCO, Saraiva JFK, Chacra APM, Bianco HT, Afiune AN, et al. Arquivos brasileiros de cardiologia. 2017;109(2 Supl 1):1-76. 14. DongH,ChenW,WangX,PiF,WuY,PangS,etal.ApolipoproteinA1,B levels, andtheirratioandtheriskofafirststroke:ameta-analysisandcase-controlstudy. Metab BrainDis. 2015;30(6):1319-30. References This is an open-access article distributed under the terms of the Creative Commons Attribution License 110